The TCGA pancancer study also teaches us that the proportion of tumors with mutated CDKN2A with respect to deletions is among the highest in pancreatic cancer (together with bladder cancer, non-small cell lung cancer, melanoma) (Figure 6). This evidence concerns the gene CDKN2A and pancreatic neoplasm.